<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958928</url>
  </required_header>
  <id_info>
    <org_study_id>Termination-AF</org_study_id>
    <nct_id>NCT04958928</nct_id>
  </id_info>
  <brief_title>Termination of Persistent Atrial Fibrillation by Catheter Ablation</brief_title>
  <official_title>A Prospective, Multicenter, Cohort Study of Termination of Persistent Atrial Fibrillation by Catheter Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuhan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiamen Cardiovascular Hospital, Xiamen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Chengdu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Chest Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter, cohort study aims to demonstrate the role of termination&#xD;
      of AF in ablation for persistent atrial fibrillation, and evaluate the clinical outcomes in&#xD;
      patients with or without AF termination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AF recurrence rate</measure>
    <time_frame>12 months</time_frame>
    <description>AF recurrence is defined as presence of documented AF episodes of 30 recurrence is defined as presence of documented AF episodes of 30 seconds or longer duration.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Persistent AF Group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation</intervention_name>
    <description>All patients received radiofrequncy ablation.</description>
    <arm_group_label>Persistent AF Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with persistent AF.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Aged 18 to 80 years old; 2. Persistent AF; 3. Nonresponse or intolerance to â‰¥1&#xD;
        antiarrhythmic drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. With uncontrolled congestive heart failure;&#xD;
&#xD;
          2. Having significant valvular disease and/or prosthetic heart valve(s);&#xD;
&#xD;
          3. With myocardial infarction or stroke within 6 months of screening;&#xD;
&#xD;
          4. With Significant congenital heart disease;&#xD;
&#xD;
          5. Ejection fraction was &lt;40% measured by echocardiography;&#xD;
&#xD;
          6. Allergic to contrast media;&#xD;
&#xD;
          7. Contraindication to anticoagulation medications;&#xD;
&#xD;
          8. Severe pulmonary disease e.g. restrictive pulmonary disease, chronic obstructive&#xD;
             disease (COPD);&#xD;
&#xD;
          9. Left atrial (LA) thrombus measured by pre-procedure transesophageal echocardiography;&#xD;
&#xD;
         10. Having any contraindication to right or left sided heart catheterization; 11. Previous&#xD;
             atrial fibrillation ablation;&#xD;
&#xD;
        12. Presence of an implanted cardioverter-defibrillator; 13. Any cardiac surgery within the&#xD;
        past 2 months; 14. Poor general health; 15.Life expectancy less than 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qin Mu, MD</last_name>
    <phone>+8613052320103</phone>
    <email>qinmuae@163.com</email>
  </overall_contact>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Chest Hospital</investigator_affiliation>
    <investigator_full_name>Xu Liu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

